Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis

The comparative risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving tenofovir disoproxil fumarate (TDF) vs. entecavir (ETV) remains controversial. In this individual patient data (IPD) meta-analysis, we aimed to compare HCC risk between the two drugs and ident...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2023-03, Vol.78 (3), p.534-542
Hauptverfasser:	Choi, Won-Mook, Yip, Terry Cheuk-Fung, Wong, Grace Lai-Hung, Kim, W. Ray, Yee, Leland J., Brooks-Rooney, Craig, Curteis, Tristan, Cant, Harriet, Chen, Chien-Hung, Chen, Chi-Yi, Huang, Yi-Hsiang, Jin, Young-Joo, Jun, Dae Won, Kim, Jin-Wook, Park, Neung Hwa, Peng, Cheng-Yuan, Shin, Hyun Phil, Shin, Jung Woo, Yang, Yao-Hsu, Lim, Young-Suk
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - etiology Chronic hepatitis B entecavir Female Hepatitis B e Antigens Hepatitis B, Chronic - drug therapy hepatocellular carcinoma Humans individual patient data Liver Neoplasms - etiology Male meta-analysis Middle Aged Retrospective Studies Tenofovir - therapeutic use tenofovir disoproxil fumarate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!